MPLT — MAPLIGHT THERAPEUTICS INC
什么是 13F 持仓报告?谁需要申报、何时申报 · 13F 持仓报告看不到什么
最后更新: 2026-11-14 · 来源: SEC EDGAR Form 13F-HR
截至Q2 2026,共 114 家机构在其最新 13F 申报中持有 MPLT(MAPLIGHT THERAPEUTICS INC),合计申报市值 $958.95M,对应 28.18M 股。按股数计算较上季度增持 7.1%(+1.67M 股),申报市值环比上升 79.0%。持仓集中度较高:前五大持有人占申报市值的 48.8%,前十大的集中度为 66.3%。
与上一季度相比,42 家新建仓位、23 家加仓、30 家减仓、13 家清仓退出。13F 数据为季末快照,以上变动反映的是 Q2 2026 末的持仓状态,并非实时交易。
MAPLIGHT THERAPEUTICS INC(MPLT)的主要机构持有人包括 Novo Holdings A/S、FCPM III SERVICES B.V.、T. Rowe Price Investment Management, Inc.,按 13F 申报市值在本页 147 家持有人中排名居前。
MPLT 属于Health Care板块。
本页所有数据均来自美国证监会(SEC)13F 季度申报。13F 申报人需在季度结束后 45 天内披露 10 万美元以上的多头持仓;空头、期权对冲与季度内交易不在其列,因此这些数字反映的是机构持仓的季度快照,而非实时仓位。
机构逐季持仓趋势
| 季度 | 持有机构数 | 股数 | 金额 | 环比净变动 |
|---|---|---|---|---|
| Q3 2026 | 59 | 11.42M | $116.40M | +42.1% |
| Q2 2026 | 114 | 28.18M | $958.95M | +7.1% |
| Q1 2026 | 85 | 25.16M | $509.26M | +8.4% |
| Q4 2025 | 77 | 23.43M | $411.44M | — |
表内 4 个季度中,机构持股合计减少 51%(Q4 2025 → Q3 2026);单季变动最大的是 Q1 2026(+8.4%)。
前 25 大机构持仓人(Q3 2026) — 25 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 2.30M | $23.44M | 15.84% | 增持 | |
| 1.71M | $17.45M | 0.00% | 增持 | |
| 1.54M | $15.71M | 0.00% | 增持 | |
| 912.04K | $9.29M | 1.48% | 持有 | |
| 612.31K | $6.24M | 0.01% | 增持 | |
| 611.45K | $6.23M | 2.54% | 持有 | |
| 556.37K | $5.67M | 1.07% | 减持 | |
| 440.73K | $4.49M | 0.00% | 增持 | |
| 415.76K | $4.24M | 0.00% | 持有 | |
| 396.08K | $4.04M | 0.00% | 减持 | |
| 313.59K | $3.20M | 0.00% | 减持 | |
| 245.22K | $2.50M | 0.00% | 增持 | |
| 170.86K | $1.74M | 0.00% | 持有 | |
| 140.89K | $1.43M | 0.00% | 增持 | |
| 120.87K | $1.23M | 0.00% | 增持 | |
| 116.46K | $1.19M | 0.00% | 减持 | |
| 102.23K | $1.04M | 0.00% | 减持 | |
| 85.81K | $874.43K | 0.00% | 增持 | |
| 83.74K | $853.00K | 0.00% | 增持 | |
| 83.27K | $848.56K | 0.00% | 增持 | |
| 74.48K | $759.00K | 0.01% | 新进 | |
| 60.72K | $618.70K | 0.00% | 增持 | |
| 59.17K | $602.97K | 0.00% | 增持 | |
| 58.46K | $595.72K | 0.01% | 增持 | |
| 30.96K | $315.45K | 0.00% | 增持 |
更早季度的机构持仓记录(逐季列表): 返回前 25 大机构持仓人
Q2 2026 — 25 家基金
Q1 2026 — 25 家基金
Q4 2025 — 25 家基金
新建仓(Q2 2026)
- Paradigm Biocapital Advisors LP 685.85K 股 · $24.58M
- Capital World Investors 415.73K 股 · $14.90M
- Capital World Investors 415.73K 股 · $14.90M
- GEODE CAPITAL MANAGEMENT, LLC 402.05K 股 · $14.41M
- Sixth Street Partners Management Company, L.P. 136.82K 股 · $4.90M
- Millennium Management 128.84K 股 · $4.62M
- MILLENNIUM MANAGEMENT LLC 128.84K 股 · $4.62M
- Boxer Capital Management, LLC 75.00K 股 · $2.69M
- Trexquant Investment LP 63.79K 股 · $2.29M
- HRT FINANCIAL LP 51.98K 股 · $1.86M
- Jain Global LLC 45.55K 股 · $1.63M
- BRIDGEWAY CAPITAL MANAGEMENT, LLC 35.00K 股 · $1.25M
完全清仓(较上季)
- Vestal Point Capital, LP 卖出 420.00K 股 · $8.54M
- STATE STREET CORP 卖出 339.12K 股 · $6.89M
- RA CAPITAL MANAGEMENT, L.P. 卖出 248.29K 股 · $5.05M
- Board of Trustees of The Leland Stanford Junior University 卖出 199.23K 股 · $4.05M
- Tetragon Partners GP Ltd 卖出 112.11K 股 · $2.28M
- Janus Henderson Group 卖出 54.75K 股 · $1.11M
- TUDOR INVESTMENT CORP ET AL 卖出 36.74K 股 · $746.92K
- Walleye Capital LLC 卖出 11.57K 股 · $235.26K
- STRS OHIO 卖出 3.00K 股 · $60.99K
- CWM, LLC 卖出 57 股 · $1.16K
- Root Financial Partners, LLC 卖出 28 股 · $569
- MAI Capital Management 卖出 12 股 · $244
基金持仓历史 — 各季度股数(前 20 只基金)
| 基金 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 |
|---|---|---|---|---|
| Nan Fung Group Holdings Ltd | 2.30M | 971.25K | 971.25K | 971.25K |
| BlackRock Inc | 1.71M | 1.03M | 1.34M | 1.10M |
| Fidelity Management & Research (FMR) | 1.54M | 823.56K | 204.50K | 904 |
| Sanofi | 912.04K | 912.04K | 912.04K | 912.04K |
| Marshall Wace | 612.31K | 5.80K | — | 39.66K |
| Pivotal bioVenture Partners Investment Advisor LLC | 611.45K | 611.45K | 611.45K | 611.45K |
| Blue Owl Capital Holdings LP | 556.37K | 729.93K | 1.01M | 327.06K |
| Geode Capital Management | 440.73K | 402.05K | 481.20K | 389.03K |
| Capital World Investors | 415.76K | 415.73K | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 396.08K | 784.15K | 719.82K | — |
| STATE STREET CORP | 313.59K | — | 339.12K | 229.48K |
| BNP PARIBAS FINANCIAL MARKETS | 245.22K | 70.48K | 37.30K | 3.46K |
| BNP Paribas Asset Management Holding S.A. | 170.86K | 170.86K | 267.75K | 147.93K |
| TD ASSET MANAGEMENT INC | 140.89K | 54.53K | 47.77K | 36.96K |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 120.87K | 96.76K | 112.60K | — |
| VANGUARD FIDUCIARY TRUST CO | 116.46K | 123.14K | 131.23K | — |
| UBS Group AG | 102.23K | 122.03K | 236.51K | 18.29K |
| BARCLAYS PLC | 85.81K | 12.97K | 5.79K | 26.41K |
| HRT FINANCIAL LP | 83.74K | 51.98K | — | — |
| Manulife Financial | 83.27K | 7.04K | — | — |
▲ 低买(基金新建/增持,下一季股价上涨 ≥5%) ▼ 高卖(基金减持,下一季股价下跌 ≥5%)
拖拽/滚轮缩放 · 默认显示最近一年 · 标注来自 13F 申报中的季度基金操作 · 悬停查看详情
常见问题
Which funds hold MPLT?
As of 2026-Q2, 114 institutional funds reported holding MPLT (MAPLIGHT THERAPEUTICS INC) in SEC 13F filings, with a combined reported value of $958.95M.
How many shares of MPLT do institutions own?
13F filers reported 28.18M shares of MPLT, worth $958.95M in aggregate at the end of 2026-Q2.
Is institutional ownership of MPLT rising or falling?
Share counts moved +7.1% versus the prior quarter — accumulation.
Who are the top institutional holders of MPLT?
The largest 13F holders are Novo Holdings A/S, FCPM III SERVICES B.V., T. Rowe Price Investment Management, Inc., Goldman Sachs Group, PRICE T ROWE ASSOCIATES INC /MD/; the top 25 are ranked at the top of this page.
Who are the major shareholders of MAPLIGHT THERAPEUTICS INC?
The major shareholders of MAPLIGHT THERAPEUTICS INC (MPLT) by reported 13F value are Novo Holdings A/S, FCPM III SERVICES B.V., T. Rowe Price Investment Management, Inc., Goldman Sachs Group, PRICE T ROWE ASSOCIATES INC /MD/, among 147 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.